PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of up to Two De Novo Coronary Artery Lesions - Pharmacokinetics Sub-trial
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Pharmacokinetics; Registrational
- Acronyms PLATINUM-PK
- Sponsors Boston Scientific Corporation
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 14 Nov 2012 New trial record